Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 12, 2008 Brian Lawler	Hep C Drugs Slug It Out Does Vertex's telaprevir really trump Schering's boceprevir?
The Motley Fool August 11, 2010 Brian Orelli	Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool December 14, 2006 Brian Lawler	Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
The Motley Fool January 24, 2008 Brian Lawler	Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note.
The Motley Fool June 13, 2007 Brian Lawler	Tracking Vertex The pharmaceutical updates investors on the progress of its lead compound.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
The Motley Fool August 4, 2010 Brian Orelli	No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's.
The Motley Fool May 23, 2008 Brian Lawler	Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay.
The Motley Fool April 23, 2008 Brian Lawler	Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir.
The Motley Fool April 29, 2008 Brian Lawler	So Pharmasset, So Good Early data hints at a promising hepatitis C treatment.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool April 1, 2008 Brian Lawler	Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool October 30, 2006 Brian Lawler	Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data.
The Motley Fool August 4, 2008 Brian Lawler	Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline.
The Motley Fool September 26, 2008 Brian Lawler	Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages.
The Motley Fool January 28, 2008 Brian Lawler	Vertex Has a Lot to Prove Vertex Pharmaceuticals announces that final results from its upcoming phase 3 trials wouldn't be ready until the middle of 2010, a far cry from the filing in 2008 that Vertex was previously forecasting.
The Motley Fool October 31, 2007 Brian Lawler	The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note.
The Motley Fool July 25, 2007 Brian Lawler	Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool November 6, 2007 Brian Lawler	No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns?
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
The Motley Fool August 4, 2010 Ryan McBride	How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals.
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool May 17, 2011 Luke Timmerman	Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex.
The Motley Fool May 27, 2005 Charly Travers	Vertex's Cautious Optimism The company's innovative hepatitis C drug has made May a month to remember. Investors, take note.
The Motley Fool June 27, 2008 Brian Lawler	Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker.
The Motley Fool January 8, 2008 Brian Lawler	InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C.
The Motley Fool April 26, 2011 Luke Timmerman	FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex?
The Motley Fool July 27, 2011 Alexander Crawford	Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve?
The Motley Fool February 10, 2005 Charly Travers	Focus on the Pipeline Vertex Pharmaceuticals is losing money. But it has at least one drug that makes the future look brighter.
The Motley Fool March 4, 2009 Brian Orelli	Vertex Combines to Keep From Being Ground Up Vertex Pharmaceuticals announces that it is buying ViroChem Pharma, getting two early stage hepatitis C compounds in the deal.
The Motley Fool January 21, 2011 Brian Orelli	Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir.
The Motley Fool July 24, 2007 Brian Lawler	Discounting InterMune Shares of InterMune fall after analyst worries about one of its drugs. Investors looking to buy into the next blockbuster class of hepatitis C treatments on the cheap just got their chance.
The Motley Fool July 10, 2009 Brian Orelli	Vertex Pulls a Wimpy After four follow-on stock offerings in the last three years, Vertex Pharmaceuticals finally has a plan to raise some cash that won't dilute its shareholders.
The Motley Fool April 27, 2005 Charly Travers	Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent.
The Motley Fool January 30, 2009 Brian Orelli	Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients.
The Motley Fool June 15, 2007 Brian Lawler	Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week.
The Motley Fool September 11, 2007 Brian Lawler	Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely.
The Motley Fool July 27, 2011 Brian Orelli	Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.
The Motley Fool April 3, 2008 Brian Lawler	Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug.
The Motley Fool October 28, 2011 Brian Orelli	Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug.
The Motley Fool June 9, 2011 Brian Orelli	It's a Numbers Game With Vertex In the longer term, the number of patients Vertex can address with its cystic fibrosis drugs will play a major role in its valuation.
The Motley Fool April 13, 2011 Brian Orelli	Drug Duo Escapes Advisory Panel Unharmed Pfizer and Novartis are on their way to expanding their cancer drug indications.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
The Motley Fool January 17, 2008 Brian Lawler	The Good Times Roll for Pharmasset Shares ride high after the company releases positive clinical trial data.